Acquiring Company
Amgen
Acquired Company
ChemoCentryx
Thousand OaksBiotechnologyHealth CareBiotechnologyHealth CareTherapeuticsPharmaceuticalDescription
Amgen (NASDAQ: AMGN) and ChemoCentryx, Inc., (NASDAQ: CCXI), a biopharmaceutical company focused on orally administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, today announced that the companies have entered into a definitive agreement under which Amgen will acquire ChemoCentryx for $52 per share in cash, representing an enterprise value of approximately $3.7 billion.
Quick answer
Amgen is acquiring ChemoCentryx for $4 billion, announced August 4, 2022. Amgen is based in Thousand Oaks, California, United States.
- How much did Amgen pay for ChemoCentryx?
- The reported deal value is $4 billion.
- What does Amgen do?
- Amgen harnesses the best of biology and technology to fight the world’s toughest diseases, and make people’s lives easier, fuller and longer.
- Where are Amgen and ChemoCentryx based?
- Amgen is based in Thousand Oaks, California, United States.
- Who are the decision-makers at Amgen?
- Fundz holds 2 contacts at Amgen. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Therapeutics and Pharmaceutical
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Bristol Myers Squibb And Turning Point Therapeutics Announce Expiration Of Hsr Act Waiting Period And Clearance From Federal Cartel Office Of Germany Related To Pending Acquisition Of Turning Point Therapeutics (August 16, 2022)
- Bristol Myers Squibb Completes Acquisition Of Turning Point Therapeutics, Expanding Precision Oncology Portfolio (August 17, 2022)
- Pfizer To Acquire Global Blood Therapeutics For $5.4 Billion To Enhance Presence In Rare Hematology, $5.4B (August 8, 2022)
- Gurnet Point Capital And Patient Square Capital Complete Their Acquisition Of Radius Health, Inc. (August 15, 2022)
- Rafa Laboratories To Acquire A Significant Stake In Exceed Orphan And Expand Its International Capabilities In Medicines Addressing Rare Diseases (August 1, 2022)
- Gilead Sciences To Acquire Mirobio (August 4, 2022)
Who to call at Amgen, and when
When Amgen changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Amgen raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Amgen, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Amgen. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Amgen makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired ChemoCentryx?
ChemoCentryx was acquired by Amgen, based in Thousand Oaks. The deal was reported on August 4, 2022. Amgen harnesses the best of biology and technology to fight the world’s toughest diseases, and make people’s lives easier, fuller and longer. Amgen is publicly traded (AMGN) and operates in Biotechnology.
When did Amgen acquire ChemoCentryx?
Amgen's acquisition of ChemoCentryx was reported on August 4, 2022. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does ChemoCentryx do?
ChemoCentryx is a biopharmaceutical company commercializing and developing new medications for inflammatory and autoimmune diseases and cancer. It is privately held, operating in Biotechnology.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.